Sensorion announced the appointment of Khalil Barrage as Interim Chair of the Board. Mr. Barrage will replace Scott D. Myers, who has informed the Board that he will step down to manage other commitments, as he was recently appointed as Chief Executive Ocer of Viridian Therapeutics Inc. Mr. Barrage has served on the Board of Sensorion for over three years, supporting with several capital raises and providing leadership on the Company's evolution towards becoming a gene therapy-focused company. He has been a managing director at Invus Group, a major investor in Sensorion, for nearly 20 years, heading its Public Equity group and serves on the Boards of Elevate Bio, Onxeo, Orthobond and Protagenic Therapeutics.

He is also a Board member of the Children of Armenia Fund and Solving Kids Cancer. Mr. Barrage holds a BA from the American University of Beirut. Sensorion has commenced a search process to appoint a new independent Chair of the Board and will provide an update in due course.